Martyna Wroblewska, Author at BaseLaunch

All Features

What startups need to know about term sheets, legal due diligence and employee incentives

What startups need to know about term sheets, legal due diligence and employee incentives Conducting legal due diligence and preparing and negotiating term sheets for…

Martyna Wroblewska13.01.2023

All Features

Building biotech companies and raising venture capital financing

Building biotech companies and raising venture capital financing In our latest event co-organized with Pureos, we had three extraordinary biotech founders (one of them who…

Martyna Wroblewska05.01.2023

All Features

Raising $50M series A with Cimeio Therapeutics

Martyna Wroblewska01.12.2022

All Featured Portfolio news

NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage

NXI Therapeutics (formerly Nextimmune), the specialist biotech developing next generation immunosuppressive drugs for autoimmune diseases and organ transplantation, today announces that it has appointed Dr…

Martyna Wroblewska30.11.2022

All Features

Basel – A Major Powerhouse in Cancer Research

Stephan Emmerth, Director Business Development & Operations BaseLaunch and Paul Eschmann, Head of International Markets and Business Affairs Basel Area Business & Innovation, describe the…

Martyna Wroblewska19.10.2022

All Interviews

Podcast: Never underestimate the true value of IP with Philipp Marchand

If you invent something and want to sell it and make a profit there is no way around one major topic: protecting your intellectual property,…

Martyna Wroblewska10.10.2022

All Portfolio news

Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022

Anaveon, a clinical-stage immuno-oncology company, announced updated clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as…

Martyna Wroblewska27.09.2022

All

BaseLaunch and WuXi Biologics announce their partnership

We are pleased to announce the partnership between BaseLaunch and WuXi Biologics! WuXi Biologics is a global Contract Research, Development and Manufacturing Organization with operations…

Martyna Wroblewska26.09.2022

All Features

Three Pillars for Setting up Biotech Startups for Success

No biotech startup can walk the path to success all alone and unprepared, especially not without the three pillars of Data, Strategy and Team, as…

Martyna Wroblewska21.09.2022

All Portfolio news

Phialogics joins BaseLaunch Portfolio

We are excited to welcome Phialogics as our newest portfolio company! Basel, Switzerland. 20 September 2022 - Phialogics is a preclinical stage company developing cell-type-specific…

Martyna Wroblewska20.09.2022

Martyna Wroblewska

What startups need to know about term sheets, legal due diligence and employee incentives

Building biotech companies and raising venture capital financing

Raising $50M series A with Cimeio Therapeutics

NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage

Basel – A Major Powerhouse in Cancer Research

Podcast: Never underestimate the true value of IP with Philipp Marchand

Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022

BaseLaunch and WuXi Biologics announce their partnership

Three Pillars for Setting up Biotech Startups for Success

Phialogics joins BaseLaunch Portfolio

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us